Board of Directors

The ACS Biomarker Supervisory Board has broad experience in setting up and guiding biotech start-up companies. The Supervisory board oversees the strategic, organizational policy making and operational activities of the Management Board.

Harm de Vries

Harm is co-founder and manager of several high-tech venture capital funds: the Erasmus MC Biomedical Fund (2007), the Life Sciences Fund Amsterdam (2009) and the Twente Technology Fund (2010). On behalf of these funds, Harm is member of the board of several portfolio companies as a non-executive director. From 1999 to 2006, Harm de Vries worked as the general counsel at Life Sciences Partners (LSP), a bio-tech VC fund with € 500 million under management and offices in Amsterdam, Munich and Boston. In 2005, Harm authored a guide on venture capital best practices: ‘Venture Capital Term Sheets, a guide to structuring and negotiating venture capital transactions’. Harm started his career as a lawyer with international law firm (1995-1999). He holds a degree in Law from Erasmus University Rotterdam. 

Marcel Kloosterman

Marcel Kloosterman, PhD has worked for DSM since 1985 in various functions ranging from market research and business development to new business creation before joining DSM Venturing. His fields of interest and expertise span the areas of Life Sciences, Performance Materials and Clean Tech. Since 2006 he has been investment manager for Limburg Ventures, where he holds several board positions in portfolio companies.  Since 2010 Marcel is also active as investment manager for Nedermaas High Tech Ventures and in various European advisory boards.

Bookmark and Share